GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Growth Rank

Scandion Oncology A/S (OSTO:SCOL) Growth Rank : 0 (As of Jun. 08, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S Growth Rank?

Scandion Oncology A/S has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Scandion Oncology A/S Growth Rank Related Terms

Thank you for viewing the detailed overview of Scandion Oncology A/S's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Scandion Oncology A/S (OSTO:SCOL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Growth Rank
Comparable Companies
OSTO:EXPRS2 OSTO:COMBI XSAT:ABERA OSTO:LPGO NGM:COEGIN XSAT:CHOSA OSTO:2CUREX OSTO:BIOSGN XSAT:APTA XSAT:DBP B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
8VY:Germany
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Website
https://www.scandiononcology.com
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines